Tymlos (Abaloparatide) in Your 50s: What Women in Menopause Need to Know

What Is Tymlos and Why Does It Matter in Your 50s?

Tymlos is a synthetic analogue of parathyroid hormone-related protein (PTHrP). Unlike antiresorptive drugs, which slow bone breakdown, Tymlos actively builds new bone. For women entering menopause in their 50s, that distinction matters enormously: estrogen withdrawal accelerates bone resorption so sharply that a woman can lose up to 20% of her bone density in the first 5 to 7 years after menopause, making the early postmenopausal decade a critical window.

Women in their 50s who already carry low bone density, a prior fragility fracture, or multiple clinical risk factors may qualify for Tymlos rather than a standard bisphosphonate. The FDA approved abaloparatide in April 2017 specifically for postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors, or failure or intolerance of other therapies.

Why Your 50s Are a High-Stakes Decade for Bone

Your 50s are typically when menopause arrives (median age in the United States: 51.4 years). The sharp drop in estrogen removes a key brake on osteoclast activity. Bone turnover markers spike, trabecular (spongy) bone in vertebrae and wrist thins faster than cortical bone, and fracture risk climbs even before a DEXA scan reaches the technical threshold of osteoporosis (T-score at or below -2.5).

A woman who reaches her late 50s having already had one vertebral fracture faces roughly a fivefold increased risk of a second vertebral fracture compared to a woman with the same T-score but no prior fracture history. That is the population where Tymlos was built to work.

How Abaloparatide Differs from Teriparatide

Both abaloparatide and teriparatide (Forteo) are anabolic agents that act on the PTH-1 receptor. Abaloparatide selectively stimulates the RG conformation of the PTH-1 receptor, which preferentially drives bone formation with less stimulation of bone resorption signaling compared to teriparatide. In head-to-head data from the ACTIVE trial, abaloparatide produced a numerically greater gain in lumbar spine BMD at 18 months (+9.2%) versus teriparatide (+7.8%), though both were superior to placebo.

The ACTIVE Trial: What the Data Actually Show for Women

The ACTIVE trial (Abaloparatide Comparator Trial In Vertebral Endpoints) enrolled 2,463 postmenopausal women aged 49 to 86 across multiple countries. Participants were randomized to abaloparatide 80 mcg daily, teriparatide 20 mcg daily, or placebo by subcutaneous injection for 18 months.

Fracture Outcomes

At 18 months, new morphometric vertebral fractures occurred in:

• 0.58% of the abaloparatide group
• 0.84% of the teriparatide group
• 4.22% of the placebo group

That translates to an 86% relative risk reduction versus placebo for vertebral fractures and a 43% reduction in non-vertebral fractures for abaloparatide.

The ACTIVExtend study then followed ACTIVE participants for an additional 24 months of alendronate after stopping Tymlos. Women who had received abaloparatide in ACTIVE and then transitioned to alendronate maintained significantly more bone density and had fewer fractures than those who had been on placebo followed by alendronate. This confirms that sequential therapy is not optional. It is the standard of care.

BMD Gains by Site

At 18 months, abaloparatide produced mean BMD increases of:

• Lumbar spine: +9.2%
• Total hip: +3.6%
• Femoral neck: +3.6%

These are clinically meaningful gains. A 1% increase in femoral neck BMD correlates with approximately a 3% reduction in hip fracture risk, which puts a 3.6% hip gain in real-world perspective.

Where the Evidence Has Gaps

ACTIVE enrolled predominantly white women (approximately 80%). Women of color, women with early surgical menopause, and women under 50 years of age were not well represented. The Bone Health and Osteoporosis Foundation notes that Black women are less likely to be diagnosed or treated for osteoporosis despite having comparable absolute fracture risk in some age groups. If you are a woman of color in your 50s reading this, that evidence gap is real, and your clinician should apply clinical judgment rather than assuming trial results apply uniformly.

Sex-Specific Physiology: Why Estrogen Status Changes Everything

Tymlos is approved only for postmenopausal women. That is not arbitrary. The anabolic response to PTH-receptor agonists is modulated by estrogen: estrogen status affects osteoblast lifespan and the balance between bone formation and resorption at the cellular level.

What "Postmenopausal" Means Clinically for Tymlos Eligibility

For most women in their 50s, menopause is defined as 12 consecutive months of amenorrhea without another cause. Surgical menopause after bilateral oophorectomy at any age counts. Menopause induced by cancer treatment also counts.

Women who are perimenopausal (still having irregular cycles) are not the target population. Tymlos has not been studied in premenopausal or perimenopausal women. This is an evidence gap, not a theoretical one.

The Role of Concurrent Hormone Therapy

Some women in their early 50s are on menopausal hormone therapy (MHT) for vasomotor symptoms while also meeting criteria for osteoporosis treatment. MHT does reduce bone loss, but it is not considered adequate fracture protection for women who already have osteoporosis with high fracture risk. A 2022 position statement from The Menopause Society acknowledges MHT as bone-protective but does not recommend it as primary therapy when anabolic treatment is indicated. You can take Tymlos and MHT concurrently. There is no pharmacokinetic interaction of clinical significance, and combined use was not excluded in the ACTIVE trial.

Dosing, Administration, and What to Expect Day to Day

The approved dose is abaloparatide 80 mcg subcutaneously once daily, injected into the periumbilical abdomen using the prefilled pen device. You give it at roughly the same time each day. There is a transient dip in blood pressure for the first few hours after injection, which is why the FDA label recommends injecting while sitting or lying down for the first several doses.

The First-Dose Experience

Orthostatic hypotension, dizziness, nausea, and palpitations tend to cluster in the first 4 to 8 weeks. In the ACTIVE trial, 3.2% of abaloparatide-treated women discontinued due to adverse events versus 1.8% in the placebo group, with dizziness and nausea leading the list. Most women who push through the first month tolerate subsequent doses well.

Practical tip: inject in the morning, stay seated for 20 to 30 minutes, and have a small meal before injection if nausea is a problem.

Monitoring While on Tymlos

Your clinician should check:

• Serum calcium before starting (Tymlos is contraindicated in uncorrected hypercalcemia)
• 24-hour urine calcium at 3 months (mild hypercalciuria occurs in some women)
• DEXA at baseline and after 18 months (or sooner if clinically indicated)
• Bone turnover markers (P1NP or CTX) at 3 to 6 months to confirm anabolic response

The DEXA results during Tymlos therapy may underestimate true structural bone quality gains because Tymlos also improves bone microarchitecture and cortical thickness in ways areal BMD does not fully capture.

Injection Site and Storage

The pen device stores unopened in the refrigerator (36 to 46°F). Once the pen is in use, it can be kept at room temperature below 77°F for up to 30 days. Do not freeze. Do not use past the 30-day in-use window even if doses remain.

Pregnancy, Lactation, and Contraception (Required Reading)

Tymlos is contraindicated in women who are pregnant or could become pregnant.

Pregnancy Data

Abaloparatide is not approved or intended for premenopausal women, and it carries serious reproductive toxicity signals from animal studies. In rat studies, subcutaneous abaloparatide caused fetal harm including skeletal abnormalities at doses relevant to human exposure. There are no adequate human data in pregnant women because the drug should not be used in pregnancy.

If you are in your early 50s and have not yet had 12 consecutive months without a period, you should use reliable contraception while on Tymlos. Perimenopause does not mean you cannot conceive. Ovulation can occur unpredictably even during irregular cycles. A barrier method or hormonal contraception appropriate to your menopausal transition stage is the right conversation to have with your clinician before starting.

Lactation

There are no human data on abaloparatide transfer into breast milk. Given the drug's mechanism and the animal reproductive toxicity data, the FDA label states that the drug should not be used during breastfeeding. For most women in their 50s using Tymlos, lactation is not a clinical concern, but it is mentioned here for completeness and because some women in early surgical menopause may be younger.

Contraception Recommendation Summary

• Confirmed postmenopausal (12+ months amenorrhea): no contraception required
• Perimenopausal or recent surgical menopause in a younger woman: use reliable contraception for the duration of treatment
• If pregnancy occurs during treatment: stop immediately and contact your clinician

Who This Is Right For and Who It Is Not

Women in Their 50s Who Are Good Candidates

• Confirmed postmenopausal status
• DEXA T-score at or below -2.5 at spine or hip, OR a prior fragility fracture (wrist, vertebra, hip) with T-score at or below -1.0
• FRAX 10-year major osteoporotic fracture probability at or above 20%, or hip fracture probability at or above 3%
• Intolerance or inadequate response to bisphosphonates or denosumab
• Early surgical menopause with accelerated bone loss and high absolute fracture risk

A practical way to think about this: the WomanRx Bone Risk Triage Framework places women into three tiers based on T-score, fracture history, and FRAX probability. Only women in Tier 3 (highest absolute risk, typically T-score at or below -2.5 plus at least one additional risk amplifier such as prior fracture, glucocorticoid use, or parental hip fracture history) are typically candidates for anabolic therapy first. Women in Tiers 1 and 2 generally start with antiresorptive agents. This framework helps avoid undertreating women who need anabolic therapy and overtreating women for whom a bisphosphonate would suffice.

Women in Their 50s Who Are Not Candidates

• Premenopausal or perimenopausal without confirmed 12-month amenorrhea (off-label, unstudied)
• Any possibility of pregnancy without reliable contraception in place
• Hypercalcemia (uncorrected)
• History of bone metastases or skeletal malignancy (the osteosarcoma signal from animal data, discussed below, makes this a hard contraindication)
• Paget disease of bone or prior external beam radiation to the skeleton
• Alkaline phosphatase elevated for unexplained reasons (possible occult Paget)
• Planned or recent orthopedic surgery (coordinate with your surgeon)

The Osteosarcoma Question

Rats given very high doses of abaloparatide developed osteosarcoma. This is the same signal seen with teriparatide. The FDA added a boxed warning to the Tymlos label for this reason. Post-marketing data to date have not shown an osteosarcoma signal in humans at clinical doses, and the American Association of Clinical Endocrinologists 2020 osteoporosis guidelines state that the absolute risk in humans appears very low. The 2-year lifetime cap on anabolic therapy is tied to this animal safety finding. Do not use Tymlos for longer than 24 months total in a lifetime.

What Happens After Tymlos: Sequential Therapy Is Non-Negotiable

Bone gained on Tymlos is lost rapidly if you stop without starting an antiresorptive drug. This is not a minor point. In the ACTIVExtend trial, women who transitioned from abaloparatide to alendronate maintained and even continued to build BMD through the 43-month total observation period, with total hip BMD continuing to increase by an additional 2.7% during the alendronate phase.

Common post-Tymlos sequential options include:

• Alendronate (Fosamax): Most studied in post-anabolic sequential therapy. Oral weekly dosing. Requires adequate 25-OH vitamin D levels.
• Zoledronic acid (Reclast): Annual IV infusion. Good option if GI intolerance limits oral bisphosphonates.
• Denosumab (Prolia): Subcutaneous injection every 6 months. Effective but requires strict adherence to dosing intervals and a transition plan if you ever stop denosumab (discontinuation causes rebound bone loss).

Your clinician should plan the post-Tymlos therapy before you start Tymlos, not after. Ask at your first prescription visit: "What antiresorptive am I transitioning to at month 18 or 24, and when do we start it?"

Conditions Common in Women in Their 50s That Affect Bone and Tymlos Decisions

PCOS

Women with PCOS who transition into perimenopause and menopause in their 50s may have had years of irregular cycles and anovulation during their reproductive years. Paradoxically, some PCOS research suggests modestly higher BMD in premenopausal years due to higher androgen levels and sometimes higher body weight, but the data are mixed and BMD advantage does not persist uniformly into postmenopause. If you have PCOS and are now postmenopausal, your fracture risk should be assessed individually with DEXA and FRAX rather than assumed to be low.

Thyroid Disease

Women in their 50s have a high prevalence of thyroid disorders, including Hashimoto thyroiditis. Chronic over-suppression of TSH (as sometimes used in thyroid cancer treatment) accelerates bone loss. If you are on levothyroxine with TSH kept below the normal range, your baseline bone risk may be higher than average, and the threshold for anabolic therapy may be reached sooner.

Glucocorticoid Use

Women with autoimmune conditions (rheumatoid arthritis, lupus, asthma) who have used oral glucocorticoids for more than 3 months at doses at or above 5 mg prednisone equivalent daily are at substantially elevated fracture risk. The ACR 2022 guideline on glucocorticoid-induced osteoporosis recommends anabolic therapy as the preferred initial treatment in very high-risk patients on chronic glucocorticoids, which places some women in their 50s on a direct path to Tymlos rather than bisphosphonates.

Vitamin D, Calcium, and the Nutritional Foundation

Tymlos works best when your nutritional foundation is solid. The drug cannot build bone without adequate calcium and vitamin D substrate.

Target levels while on Tymlos:

• Serum 25-OH vitamin D: at or above 30 ng/mL (some guidelines suggest 40 ng/mL or above for maximum benefit)
• Daily calcium intake: 1,200 mg for postmenopausal women, ideally from food first, supplements second
• Avoid taking calcium supplements within 2 hours of Tymlos injection (timing has not been formally studied but may blunt transient hypercalcemia management)

Women on Tymlos should not take more than 1,500 mg of supplemental calcium daily because hypercalciuria risk is real. A 24-hour urine calcium collected 3 months after starting can identify women who need to back off supplementation.

Real-World Cost and Access Considerations

Tymlos is a brand-name drug with no generic available as of early 2025. The list price is approximately $2,800 to $3,000 per month, which makes insurance authorization a practical necessity for most women. The manufacturer (Radius Health, now owned by Menarini) offers a patient assistance program for uninsured women below income thresholds.

FDA-approved biosimilar or generic abaloparatide does not yet exist. Prior authorization for Tymlos typically requires documented DEXA results, FRAX data, and evidence of either prior fracture or failure or intolerance of a bisphosphonate or denosumab. Ask your clinician or the WomanRx care team to submit PA documentation proactively rather than waiting for a denial.

A Note From Our Reviewer

"Women in their early 50s with osteoporosis sometimes assume they can wait a few years and start treatment later. What I tell them is that every vertebral fracture that occurs before they start therapy is a fracture they could not un-fracture. Tymlos is one of the few tools we have that actively rebuilds what estrogen loss has taken. If a woman in her 50s walks into my office with a T-score of -2.8 and a prior wrist fracture, we are having the Tymlos conversation that day." Rachel Goldberg, MD, WomanRx Editorial Board